Archive for March 5th, 2012

Merck’s Peter Kim To Webcast, At Cowen & Co. — in Boston — Tomorrow
March 5, 2012


He’s not likely to make any real news in Boston tomorrow, but we’ll likely listen in just the same. We may liveblog any real news:

. . . .Peter Kim, president of Merck Research Laboratories, is scheduled to present at the Cowen & Company 32nd Annual Health Care Conference in Boston, Mass. on March 6 at 8:40 a.m. EST. Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation. . . .

So, do stop back by — around 8:40 Eastern tomorrow morning. I doubt he’ll discuss the ragweed allergy candidate, or the FDA complete response on “Son of Vytorin” [great tag, there Matt Herper!] — but who knows?

FDA: “No, For Now” — On Lipitor®/Zetia® Combo Pill
March 5, 2012


Not remotely surprising — but Merck must now either decide to double-down, and invest anew in the combo-pill (despite the vagaries experienced with the Vytorin® combo-pill), or decide to cut its losses, and move on. Fascinating. [More of my background, here.] From the AP, then:

. . . .The Merck experimental drug combines the company’s cholesterol drug Zetia with a generic version of rival Pfizer Inc.’s Lipitor, which had been the top-selling drug of all time.

Merck says company officials will talk with the FDA to determine the next steps for trying to win approval. . . .

This actually may save Whitehouse Station some money in the longer run, if it decides to moth-ball the combo. Obviously, Lipitor® is now a cheap generic, and the jury is still out (IMPROVE-IT — due 2014) on whether statins (of which Lipitor is one) combined with Zetia® actually improve outcomes, or just lower the numbers, in blood levels, without any overall CV risk reduction effect.

Follow

Get every new post delivered to your Inbox.

Join 63 other followers